Steve Noga, MD, of Takeda Oncology discusses the latest results of the ongoing US MM-6 RW clinical trial, examining the effectiveness and safety of an in-class transition to ixazomib in combination with lenalidomide and dexamethasone in newly diagnosed multiple myeloma patients who previously received a bortezomib-based treatment. The current data of this study, presented at ASCO 2020, shows that transitioning from bortezomib to ixazomib is efficacious in prolonging therapy without impacting multiple myeloma patients’ quality of life or treatment satisfaction.
Multiple myeloma is a blood cancer associated with uncontrolled growth of plasma cells. Abnormal plasma cells – also known as myeloma cells – interfere with the production of healthy blood cells in the bone marrow. Myeloma cells also produce inactive clones of abnormal antibodies that may negatively affect the bones and kidneys. Symptoms of multiple myeloma may include: bone pain (particularly in the chest and spine), frequent infections, weakness or numbness in the legs, fatigue, confusion, excessive thirst, and constipation.
For more information about multiple myeloma and other rare cancers, visit checkrare.com/diseases/cancers/.